@entity900 or @entity3003 is commonly used with @entity136 , @entity1205 , @entity1311 , or @entity1206 as chemotherapy doublets in the treatment of advanced @entity1149 ( @entity1149 ). Several randomized trials have failed to identify major differences in survival between any of these doublets. This lack of evidence for improvement in survival with any chemotherapy regimen has created a tabula rasa where no more large randomized trials should be conducted without including a genetic analysis. @entity1 see survival as their major concern, and other considerations, such as cost and quality of life, are relegated to lower positions. Genetic alterations related to the transcription-coupled repair pathway of the @entity377 excision repair system (TC-NER) have revealed the subset of @entity1 who are resistant to @entity900 . TC-NER involves genes that are deficient in rare @entity14079 such as @entity14309 and @entity2173 . For a long time, @entity11833 mRNA levels have been known to correlate with DNA repair capacity in various tissues. Levels of DNA @entity900 adducts in peripheral blood and buccal mucosa cells predict chemotherapy response, and high @entity11833 mRNA levels have been related to chemoresistance in @entity43 and in malignant lymphocytes from @entity1072 . Moreover, in some instances, mRNA expression has been correlated with polymorphisms. Overexpression of @entity11833 correlates with poor survival in @entity136 / @entity900 -treated @entity1149 @entity1 . An ongoing customized @entity11833 -based chemotherapy trial has been designed based on this knowledge. @entity1 are randomized to the control arm of @entity900 / @entity1205 or to the experimental arm, where @entity1205 is combined with @entity900 or @entity136 according to @entity11833 levels. To date, 86 @entity1 have been included.

Genetic testing for chemotherapy in XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer'] @entity14309 :: ('MESH:D003057', 'Disease') :: ['Cockayne syndrome'] @entity11833 :: ('2067', 'Gene') :: ['ERCC1'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin', 'Cisplatin'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small-cell lung cancer'] @entity1206 :: ('MESH:C030852', 'Chemical') :: ['vinorelbine'] @entity377 :: ('CHEBI:36976', 'Chemical') :: ['nucleotide'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine'] @entity2173 :: ('MESH:D014983', 'Disease') :: ['xeroderma pigmentosum'] @entity1072 :: ('MESH:D015451', 'Disease') :: ['chronic lymphocytic leukemia'] @entity14079 :: ('MESH:D020739', 'Disease') :: ['inborn disorders'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel']
@entity1149 :: (MESH:D002289,Disease) :: ['non-small cell lung cancer']
